Pam Murphy | IR |
Mark Murray | CEO |
Michael Sofia | CSO |
William Symonds | Chief Development Officer |
David Hastings | CFO |
Koert VandenEnden | Chief Accounting Officer |
Liisa Bayko | JMP Securities |
Katherine Xu | William Blair |
Keay Nakae | Chardan |
Madhu Kumar | B. Riley FBR |
Good afternoon, ladies and gentlemen, and welcome to the Arbutus Biopharma Second Quarter 2018 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder this conference call is being recorded. I'll now turn the call over to Pam Murphy, who has recently joined the Arbutus team as their IR Consultant.
You may begin.
Thank you, operator.